The agreement for the use of NuProbe’s NGS panel will support the accelerated development of Angle’s pan-cancer assay.

Most patients with advanced prostate cancer or urothelial cancer are not undergoing next-generation sequencing, a new study suggests.

Market Growth Driven by Advancements in Genomic Research, Rising Demand for Personalized Medicine, and Key Applications in ...

Integrated DNA Technologies (IDT) has introduced the Archer VARIANTPlex Lymphoma panel, a new tool for next-generation sequencing (NGS) to add to its ...

Metagenomic sequencing uses next generation sequencing (NGS) to rapidly identify and analyze microbial community diversity and understand the role of constituent species. Our proprietary microbial ...

Venlo, The Netherlands, and Hombrechtikon, Switzerland, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PreAnalytiX GmbH, a joint venture between QIAGEN ...

A new consensus definition for high-risk myeloma patients and promising results from trials dedicated to their care may offer ...

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE. Option for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs wit ...

Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, ...

ANGLE plc has signed an agreement with NuProbe USA to use its pan-cancer next generation sequencing panel. NuProbe has granted ANGLE plc an option for an exclusive global license to the NGS panel ...

Report on how AI is driving market transformation- The global bioinformatics market size is estimated to grow by USD ...